NeuroVive Pharmaceutical AB Debt/Equity
What is the Debt/Equity of NeuroVive Pharmaceutical AB?
The Debt/Equity of NeuroVive Pharmaceutical AB is 0.42
What is the definition of Debt/Equity?
Debt to equity ratio is a financial ratio indicating the relative proportion of shareholders’ equity and debt used to finance a company’s assets.
lfy (last fiscal year)
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Debt/Equity of companies in the Health Care sector on OTC compared to NeuroVive Pharmaceutical AB
What does NeuroVive Pharmaceutical AB do?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Companies with debt/equity similar to NeuroVive Pharmaceutical AB
- Core Lithium Ltd has Debt/Equity of 0.42
- China Health has Debt/Equity of 0.42
- Vanguard Specialized Funds - Vanguard Real Estate ETF has Debt/Equity of 0.42
- Jagran Prakashan has Debt/Equity of 0.42
- Smc Electric has Debt/Equity of 0.42
- Indraprastha Medical has Debt/Equity of 0.42
- NeuroVive Pharmaceutical AB has Debt/Equity of 0.42
- PetroTal has Debt/Equity of 0.42
- West Pharmaceutical Services has Debt/Equity of 0.42
- Cybele Industries Ltd has Debt/Equity of 0.42
- Tandy Leather Factory has Debt/Equity of 0.42
- Nephros Inc has Debt/Equity of 0.42
- SiteMinder has Debt/Equity of 0.42